Catherine Ramsey's Stock Ratings

Baird Analyst

Catherine Ramsey is an analyst at Baird. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/17/2024

Overall Average Return

15.3%

Smart Score

63.8%

Overall Average Return Percentile

71st

Number of Ratings

27
Buy NowGet Alert
05/10/2024NTRABuy Now
Natera
$106.529.84%$99 → $117MaintainsOutperformGet Alert
05/08/2024WATBuy Now
Waters
$350.71-11.04%$319 → $312MaintainsNeutralGet Alert
05/03/2024TWSTBuy Now
Twist Bioscience
$44.85-10.81%$39 → $40MaintainsOutperformGet Alert
05/03/2024ILMNBuy Now
Illumina
$110.0016.36%$125 → $128MaintainsNeutralGet Alert
05/03/2024CSTLBuy Now
Castle Biosciences
$24.5038.78%$33 → $34MaintainsOutperformGet Alert
04/30/2024RVTYBuy Now
Revvity
$111.9513.44%$126 → $127MaintainsOutperformGet Alert
11/21/2023NSTGBuy Now
NanoString Technologies
——$4 → $0.75DowngradeOutperform → NeutralGet Alert
08/04/2023NSTGBuy Now
NanoString Technologies
——$13 → $10MaintainsOutperformGet Alert
08/02/2023RVTYBuy Now
Revvity
$111.9531.3%$165 → $147MaintainsOutperformGet Alert
06/05/2023CSTLBuy Now
Castle Biosciences
$24.502.04%$35 → $25MaintainsOutperformGet Alert
05/10/2023WATBuy Now
Waters
$350.71-17.88%$345 → $288MaintainsNeutralGet Alert
05/10/2023NTRABuy Now
Natera
$106.52-38.04%$65 → $66MaintainsOutperformGet Alert
05/08/2023TWSTBuy Now
Twist Bioscience
$44.85-59.87%$29 → $18MaintainsOutperformGet Alert
05/04/2023CSTLBuy Now
Castle Biosciences
$24.5042.86%$38 → $35MaintainsOutperformGet Alert
04/26/2023ILMNBuy Now
Illumina
$110.00108.18%$224 → $229MaintainsNeutralGet Alert
02/16/2023WATBuy Now
Waters
$350.71-1.63%$334 → $345MaintainsNeutralGet Alert
02/06/2023TWSTBuy Now
Twist Bioscience
$44.85-35.34%$33 → $29MaintainsOutperformGet Alert
02/01/2023WATBuy Now
Waters
$350.71-4.76%$317 → $334MaintainsNeutralGet Alert
11/08/2022NSTGBuy Now
NanoString Technologies
——$21 → $14MaintainsOutperformGet Alert
11/02/2022WATBuy Now
Waters
$350.71-9.61%$348 → $317MaintainsNeutralGet Alert
11/01/2022TMOBuy Now
Thermo Fisher Scientific
$589.5712.79%$695 → $665MaintainsOutperformGet Alert
08/17/2022ABuy Now
Agilent Technologies
$154.073.85%$155 → $160MaintainsOutperformGet Alert
08/09/2022CSTLBuy Now
Castle Biosciences
$24.5095.92%$44 → $48MaintainsOutperformGet Alert
08/03/2022WATBuy Now
Waters
$350.71-0.77%$340 → $348MaintainsOutperformGet Alert
08/03/2022EXASBuy Now
Exact Sciences
$53.5140.17%$90 → $75MaintainsOutperformGet Alert
05/25/2022ABuy Now
Agilent Technologies
$154.074.49%$155 → $161MaintainsOutperformGet Alert
02/25/2022NTRABuy Now
Natera
$106.52-6.12%$152 → $100MaintainsOutperformGet Alert

Recent Analyst Stock Rating News

Key Takeaways From Natera Analyst Ratings
Assessing Waters: Insights From 4 Financial Analysts
Breaking Down Twist Bioscience: 5 Analysts Share Their Views
Beyond The Numbers: 6 Analysts Discuss Illumina Stock
Illumina Analysts Question Grail Deal's Commercial Opportunity, Hefty Price Tag
Illumina, Inc. (NASDAQ: ILMN) announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock. 
The Sell-Side Weighs In: Was The Exact Sciences Sell-Off Overdone?
Even Exact Sciences Bulls Wonder If Expectations Are Lofty
Illumina Reported Its Fastest Top-line Growth Since 2015
Baird Weighs In On Illumina's Guidance, NovaSeq Platform
Zika Headlines Continue To Be Tailwinds For Cerus
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free